BioWorld

Aug. 8, 1996

View Archived Issues

J&J PAYING AMYLIN ANOTHER $22M AFTER LOOK AT PHASE III DATA

Read More

OTHER NEWS TO NOTE

Read More

MAGAININ GOES PRIVATE PLACEMENT ROUTE; IMMUNE RESPONSE DELAYS PUBLIC

Read More

OFF-BASE INSULIN RESTORES NEAR-NORMAL GLUCOSE TO DIABETIC TRANSGENIC

Read More